Under construction – not a live service
Sign in
Taking people in BrazilPhase 2

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Key facts

Where
Belo Horizonte, Brasília, Campinas, Curitiba, Fortaleza, Porto Alegre, Rio de Janeiro, Santo André, and São Paulo, BrazilSee the 14 sites
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07018323, who can take part

Where in Brazil

  • Belo Horizonte, Minas GeraisHospital not named in the registryTaking people
  • BrasíliaHospital not named in the registryTaking people
  • Campinas, São PauloHospital not named in the registryTaking people
  • CuritibaHospital not named in the registryTaking people
  • CuritibaHospital not named in the registryTaking people
  • Fortaleza, CearáHospital not named in the registryTaking people
  • Porto AlegreHospital not named in the registryTaking people
  • Rio de JaneiroHospital not named in the registryTaking people
  • Santo André, São PauloHospital not named in the registryTaking people
  • São PauloHospital not named in the registryTaking people
  • São PauloHospital not named in the registryTaking people
  • São PauloHospital not named in the registryTaking people
  • São PauloHospital not named in the registryTaking people
  • São PauloHospital not named in the registryTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Immunovant Sciences GmbH
Trial code
NCT07018323EU 2025-521920-31-00
Record updated
30 October 2026
Original description
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.Read full original descriptionShow less

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

Inclusion: Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures; Male or female participants aged ≥ 18 years; Participants with diagnosis of GD who are hyperthyroid despite ATD treatment; Other, more specific inclusion criteria are defined in the protocol.

Exclusion: Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy; Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk; Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation; Additional exclusion criteria are defined in the protocol.

ClinicalTrials.gov NCT07018323 · EU CTIS 2025-521920-31-00

Under construction, not live – A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease (NCT07018323) – Frontlight Research